Pfizer to use Covid and divestment cash to power growth Pfizer is in a unique position in its history with gushers of cash flowing in from everywhere. Pfizer will use this cash to power future growth through its drug pipeline, innovation, and acquisitions, which will secure promising returns and profitability for investors in the year ahead.
Not only is Pfizer is generating significant sums of cash from its COVID-19 vaccine, these sums will only increase with the planned listing of the consumer healthcare business that is owned jointly between Pfizer (32%) and GSK (68%). Pfizer had indicated its intention to sell its stake through the listing, which could generate up to $19 billion in proceeds.